Background: Smoking may affect the efficacy of chemotherapy and the incidence of adverse events. We investigated the correlation between smoking history and gemcitabine-induced neutropenia.
introduction
Gemcitabine is a deoxycytidine analogue that is widely used for many solid tumors as a single agent or in combination with other anticancer drugs [1] [2] [3] [4] . The recommended dosage regimen for gemcitabine monotherapy consists of a 4-week cycle with 1000 mg/m 2 doses administered over 30 min on days 1, 8 and 15 [1, 5] . This dosage regimen is supported by the results of a Japanese phase I study involving pancreatic cancer patients [6] . However, in daily practice, we often encounter patients who cannot tolerate the recommended 1000 mg/m 2 dose of gemcitabine because of hematological adverse events, especially neutropenia. For some patients, it has been necessary to reduce the dose of gemcitabine to less than half the recommended dose because of gemcitabine-induced neutropenia.
Several enzymes are known to be involved in gemcitabine metabolism [7] . A recent study demonstrated that singlenucleotide polymorphisms (SNPs) in the cytidine deaminase (CDA) gene, which encodes a key enzyme in gemcitabine inactivation, influence the pharmacokinetics and toxicity of gemcitabine [8] . Considering the low allele frequencies of these SNPs, however, it seems that one or more unknown factors affect the pharmacokinetics and toxicity of gemcitabine. Smoking has been identified as a factor that potentially affects the pharmacokinetics of several anticancer drugs. Recent studies have demonstrated that smoking significantly lowers exposure to irinotecan and reduces the risk of irinotecaninduced neutropenia, at least in part by modulating irinotecan metabolism [9] , and decreases the blood level of erlotinib by affecting erlotinib clearance rates [10, 11] . These findings prompted us to perform the current study to investigate the potential correlation between a history of smoking and gemcitabine-induced neutropenia. 
patients and methods

smoking history
Information about the patients' smoking history was retrieved from electronic medical records based on information recorded during patient interviews. Patients were classified into smoking and non-smoking groups based on this information. The non-smoking group comprised those who stated that they had never been smokers, and the smoking group comprised both current and ex-smokers. Since most smokers had quit after their diagnosis of cancer, there were only 11 current smokers; therefore, we pooled current and ex-smokers in this study.
statistical methods
Data are presented as the median and range, unless stated otherwise. For statistical analysis, the v 2 test for dichotomous variables or the MannWhitney U test for continuous variables was carried out. Logistic regression analysis was carried out to assess the correlation between gemcitabineinduced neutropenia and the following covariates: smoking history, age, gender, baseline neutrophil count, creatinine concentration, history of surgery for primary cancer, hemoglobin concentration, platelet count, aspartate aminotransferase (AST) concentration, alanine aminotransferase (ALT) concentration and total bilirubin concentration. P < 0.05 was regarded as significant. All statistical analyses were carried out using SAS version 9.1 (SAS Institute, Cary, NC). Table 1 . Fifty-nine patients had pancreatic cancer, 41 had hepatobiliary cancer, one had mesothelioma, one had liposarcoma and one had leiomyosarcoma. Fifty-one patients were classified into the smoking group and 52 patients into the non-smoking group. G-CSF was administered to three patients in the smoking group and eight in the non-smoking group. Baseline white blood cell (WBC) count, hemoglobin concentration and creatinine concentration were significantly higher in the smoking group, and the proportion of females was significantly higher in the non-smoking group. There was no significant difference between the numbers of patients in the smoking and nonsmoking groups.
smoking history and gemcitabine-induced neutropenia
The overall incidence of grade 3-4 neutropenia was 24% in the smoking group and 56% in the non-smoking group [odds ratio (OR) 0.244, 95% confidence interval (CI) 0.105-0.569; P < 0.001; Table 2 ]. Logistic regression analysis was carried out using gender, age, baseline neutrophil count, creatinine concentration, history of surgery for primary cancer, hemoglobin concentration, platelet count, AST concentration, ALT concentration and total bilirubin concentration. A statistician confirmed the validity of the assumption of linearity by categorizing the continuous variables in the logistic regression analysis. After logistic regression analysis, a history of smoking was retained as an independent inverse predictor of gemcitabine-induced neutropenia (OR 0.188, 95% CI 0.057-0.618; P = 0.006; Table 3 ). The incidence of grade 3-4 neutropenia during the first cycle of gemcitabine treatment was higher in the non-smoking group than in the smoking group although the difference was not found to be significant in logistic regression analysis (OR 0.201, 95% CI 0.040-1.026; P = 0.054; Table 3 ).
discussion
Gemcitabine has a wide spectrum of antitumor activity with minimal non-hematological adverse events [1] [2] [3] [4] . Although the recommended dosage regimen for gemcitabine monotherapy comprises three doses of 1000 mg/m 2 per cycle [1, 5, 6, 14] , in the present study the maximum tolerated dose of gemcitabine (i.e. the dose that could be repeatedly administered without toxicity) ranged from 130 mg/m 2 to the recommended dose of 1000 mg/m 2 (Table 1) . Thus, some patients required the gemcitabine dose to be reduced several times until a tolerable dose was reached. Actually, relative dose intensity of gemcitabine was significantly lower in the non-smoking group (Table 1) , probably reflecting the fact that gemcitabine dose reduction was more common among non-smokers because of neutropenia.
Our analysis identified a significant inverse correlation between a history of smoking and the incidence of gemcitabineinduced neutropenia among chemo-naive patients treated with gemcitabine monotherapy (OR 0.244, 95% CI 0.105-0.569; P < 0.001; Table 2 ). There were only 11 current smokers in this study, two of whom developed grade 3-4 neutropenia, so to ensure robust statistical analysis we pooled the data from the ex-smokers and current smokers. Obviously, whether a patient is a current or an ex-smoker is likely to be pertinent, so future studies are warranted to evaluate the relative incidence of neutropenia among current smokers, ex-smokers and nonsmokers. The proportion of women was significantly larger in the non-smoking group, which might have affected the current results; however, no clinically significant difference was found in gemcitabine clearance between men and women (E. Lilly, unpublished data). Smoking is known to increase the original article Annals of Oncology The smoking group comprised patients who were current and ex-smokers. The non-smoking group comprised patients who had never been smokers. WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase. proliferation rate of myeloid progenitor cells [15] [16] [17] , which might partly explain the significantly higher baseline WBC count and hemoglobin level in the smoking group in the present study (Table 1) . The lower hemoglobin level in the non-smoking group could also be attributed to the larger proportion of women in this group. It is unlikely that G-CSF support affected our current results because G-CSF was used only after development of grade 3/4 neutropenia and was more common in the non-smoking group (three patients in the smoking group and eight patients in non-smoking group). Furthermore, G-CSF was never used to maintain gemcitabine dose intensity. We initially intended to examine the correlation between smoking history and gemcitabine-induced grade 3-4 anemia and thrombocytopenia; however, the incidences of grade 3-4 anemia and thrombocytopenia were too low (3.8% for both) to allow statistical analysis. Logistic regression analysis with adjustment for age, gender, baseline neutrophil count, creatinine concentration, history of surgery for primary cancer, hemoglobin concentration, platelet count, AST concentration, ALT concentration and total bilirubin concentration identified smoking history as an independent predictive factor of gemcitabine-induced neutropenia (OR 0.188, 95% CI 0.057-0.618; P = 0.006; Table 3 ). Although the incidence of grade 3-4 neutropenia during the first cycle of treatment was higher in the nonsmoking group than in the smoking group, the difference was not significant (OR 0.201, 95% CI 0.040-1.026; P = 0.054; Table 3 ). We speculate that this was due to the small sample size of the current study.
Interestingly, Laufman et al. [18] reported that smokers have a higher absolute neutrophil count than non-smokers when treated with gemcitabine monotherapy, while smokers have a lower absolute neutrophil count when treated with docetaxel monotherapy. These findings are consistent with our current results. Several mechanisms have been posited to explain the interaction between smoking habit and other antitumor drugs. Smoking potentially affects irinotecan metabolism, lowering exposure to the drug and reducing drug-induced neutropenia, at least in part by modulating CYP3A and UGT1A1 enzymes [9] . Smoking is also thought to enhance the clearance of erlotinib and lower the level of the drug in the blood by inducing CYP1A1/CYP1A2 enzyme expression [10, 11] . More than 90% of gemcitabine administered is converted into the inactive metabolite 2#-deoxy-2#,2#-difluorouridine by CDA [7] . Given that smoking is thought to modulate the irinotecanand erlotinib-metabolizing enzymes as mentioned above, it is tempting to speculate that smoking could also affect gemcitabine metabolism by modulating CDA activity. There are other possible mechanisms. Several effects of smoking are known to persist for a long time after cessation of smoking. For example, the inflammatory response to smoking in patients with chronic obstructive pulmonary disease can continue after the patient stops smoking. Similarly, it can take at least 5 years for smoking-induced leukocytosis to resolve [17, 19, 20] . These reports prompted us to speculate that some unknown persistent change in ex-smokers also affected the current results. Further study is warranted to test this hypothesis.
In the non-smoking group, the incidence of gemcitabineinduced grade 3-4 neutropenia was 56%, which is much higher than previously reported figures, which have ranged from 20% to 30% [1, 6, 14] . In contrast, the corresponding incidence was 24% in the smoking group, which is comparable to previously reported values. Because of the high incidence of neutropenia (especially among non-smokers) and the broad range of The smoking group comprised patients who were current and ex-smokers. The non-smoking group comprised patients who had never been smokers. CI, confidence interval. original article Annals of Oncology maximum tolerated doses, physicians sometimes start with a dose <1000 mg/m 2 to avoid neutropenia and repeated reduction in doses thereafter. But this approach comes with the risk of not achieving the maximum benefit from gemcitabine and should be avoided where possible; therefore, identifying patients at high risk of developing gemcitabine-induced neutropenia will help physicians to select an optimal gemcitabine dose.
Whether smoking also affects the antitumor effect of gemcitabine could not be investigated in the current study because of the heterogeneity of the study population with respect to tumor type and treatment aim (31 patients were treated with gemcitabine as adjuvant chemotherapy). Even if smoking does not affect the antitumor effect of gemcitabine, smoking remains highly detrimental to cancer patients in many ways and is clearly not an appropriate approach to avoid gemcitabine-induced neutropenia [21] .
In summary, our present data indicate that patients without a history of smoking are at higher risk of developing grade 3-4 gemcitabine-induced neutropenia in daily clinical practice. Future studies including a larger number of patients are warranted to verify our results and to clarify the underlying mechanism. 
